Show simple item record

dc.contributor.authorRuchlemer, R
dc.contributor.authorWotherspoon, AC
dc.contributor.authorThompson, JN
dc.contributor.authorSwansbury, JG
dc.contributor.authorMatutes, E
dc.contributor.authorCatovsky, D
dc.date.accessioned2018-09-17T15:14:08Z
dc.date.issued2002-09
dc.identifier4
dc.identifier.citationBRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 pp. 952 - 958
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2724
dc.identifier.doi10.1046/j.1365-2141.2002.03716.x
dc.description.abstractWe reviewed data on 63 patients with mantle cell lymphoma (MCL) with leukaemia (n = 16) and chronic lymphocytic leukaemia (CLL, n = 47), splenectomized over a 10-year period. Primary indications for surgery were cytopenia(s) or autoimmune phenomena and progressive or refractory disease with splenomegaly. The spleens removed were on average larger in MCL (median 2.6 kg) than in CLL (1.0 kg). Splenectomy improved the blood counts in 62% of patients with MCL and 47% with stage C CLL, both with cytopenias. The MCL patients showed a decrease in the leucocytosis (medians 60.3-29.1 x 10(9) /l before and after splenectomy), whereas there was an increase in the leucocytosis in CLL (medians 24.2-44 x 10(9) /l). With a median follow up post splenectomy of 10 months (range: < 1-128), 18 patients (four MCL and 14 CLL) have not required further therapy for up to 66 months. We conclude that splenectomy is a useful treatment in MCL and advanced CLL for the correction of cytopenias, reducing the leucocyte count and allowing prolonged periods of clinical remission without therapy. Differences seen between MCL and CLL in spleen size, and in response of the leucocytosis suggest a central role for the spleen in the evolution of MCL with leukaemia.
dc.format.extent952 - 958
dc.languageeng
dc.language.isoeng
dc.publisherBLACKWELL PUBLISHING LTD
dc.titleSplenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia
dc.typeJournal Article
rioxxterms.versionofrecord10.1046/j.1365-2141.2002.03716.x
rioxxterms.licenseref.startdate2002-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF HAEMATOLOGY
pubs.notesaffiliation: Ruchlemer, R (Reprint Author), Royal Marsden MHS Trust, Acad Dept Haematol & Cytogenet, London, England. Royal Marsden MHS Trust, Acad Dept Haematol & Cytogenet, London, England. Royal Marsden MHS Trust, Dept Histopathol, London, England. Royal Marsden MHS Trust, Acad Dept Surg, London, England. keywords: mantle cell lymphoma; chronic lymphocytic leukaemia; splenectomy; refractory disease; hypersplenism keywords-plus: NATURAL-HISTORY; BCL-1 REARRANGEMENTS; SPLENIC RUPTURE; BONE-MARROW; LEUKEMIA; FEATURES; THERAPY; INVOLVEMENT; MANAGEMENT; POPULATION research-areas: Hematology web-of-science-categories: Hematology number-of-cited-references: 41 times-cited: 11 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Br. J. Haematol. doc-delivery-number: 589EZ unique-id: ISI:000177746900005 da: 2018-09-17
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume118en_US
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorCatovsky, Danielen
dc.contributor.icrauthorMatutes, Estellaen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record